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Introduction
The cytokine-mediated suppression of hepatic drug metabolizing enzymes by inflammatory disease and the relief of suppression ("de-suppression") by successful disease treatment have recently become an issue in the development of drug interaction labels for new biological products (Huang et al., 2010) . In a bellwether example, treatment of rheumatoid arthritis patients with the anti-IL6R monoclonal antibody, tocilizumab (Actemra TM , Roche/Genentech), resulted in a 1.8-fold (57% of control) decrease in the plasma AUC of the CYP3A4 substrate simvastatin (Genentech, 2010) . Along with some related in vitro characterization of IL-6 effects in human hepatocytes, this resulted in a drug interaction label that recommends caution for
Tocilizumab use with narrow therapeutic index cytochrome P450 substrates (Genentech, 2010) .
This is a drug-disease interaction, where the perceived risk of successful disease treatment is therapeutic failure due to an increase in the clearance of cytochrome P450 substrates.
Subsequently, regulatory authorities have requested in vitro and/or in vivo study data for other cytokine-modulating biologics such as Golimumab (CDER, 2009) . Unfortunately, there is only a limited understanding of the potential utility of the preclinical tools that might be used to predict the occurrence and magnitude of clinical de-suppression of cytochromes P450 enzymes by anticytokine biologic agents.
Interleukin-6 (IL-6) is an important mediator in the acute phase response (APR) (Morrone et al., 1988; Andus et al., 1989) and is relevant to the treatment of chronic diseases such as rheumatoid arthritis, as shown by the approval of Tocilizumab (Rose-John et al., 2007) . IL-6 is secreted by Kupffer cells in the liver and acts through its receptor, IL-6R (CD126), on hepatocytes to elicit a variety of effects including mediating components of the APR, hepatic regeneration and anti-apoptotic and anti-necrosis effects (Taub, 2004) . The IL-6R can bind IL-6 as a soluble or as a membrane bound protein (Rose-John et al., 2007) and the IL-6/IL-6R D M D M a n u s c r i p t # 3 8 6 7 9 6 complex must bind two monomers of gp130 membrane protein to elicit signal transduction (Waetzig et al.; Rose-John et al., 2007) .
Hepatic cytochrome P450 enzymes are known to be down-regulated during infection and inflammatory stress and this occurs across the spectrum of cytochrome P450 isoenzymes (Shedlofsky et al., 1994; Morgan et al., 1998; Cheng et al., 2003) . Cytochrome P450 downregulation is attributed to cytokine release, since various cytokines mimic the effects of infection when injected in vivo or added to hepatocytes in primary culture (Renton and Nicholson, 2000; Morgan, 2001; Aitken and Morgan, 2007) . The mechanism of cytochrome P450 pansuppression is apparently transcriptional, related to the APR, and may involve Nf-κB, although a unifying mechanism for pan-suppression is not fully elucidated. Ghose et al. (Ghose et al., 2004) have proposed that the broad down-regulation of cytochrome P450 isoenzymes may be due to inflammation-induced alteration of the subcellular location of RXRα, which is an obligate partner in the heterodimeric nuclear receptors LXR, FXR, RAR, CAR, PXR and PPARα. These nuclear receptors regulate enzymes controlling the metabolism of lipids, bile acids, steroids and xenobiotics.
Human hepatocytes have been used to investigate the effects of cytokines involved in the acute phase response on cytochrome P450 regulation (Sunman et al., 2004; Aitken and Morgan, 2007) . IL-6, LPS, TNFα, INFγ and TGFβ all caused a marked decrease in cytochrome P450 mRNA and activity levels for CYP3A4, CYP2C isoforms, and CYP2B6, albeit with different magnitudes of suppression. Studies conducted to date were done at supra-physiological concentrations of IL-6 (> 2,000 pg/mL). In healthy individuals, serum IL-6 concentrations range from 1.3-10.3 pg/mL and are increased to 2.6-123 pg/mL in some patient populations presenting with inflammation based diseases (Roytblat et al., 2000; Hidaka et al., 2001; Yilmaz et al., 2001; Arican et al., 2005; Mastroianni et al., 2005; Ataseven et al., 2006; Wang et al., 2008) .
To discern the strengths and limitations of in vitro experimentation on cytokine-mediated suppression of cytochrome P450s, this study assessed the cytochrome P450 expression concentration-response to IL-6 in primary human hepatocytes at physiologically relevant concentrations, the influence of interindividual variability across donors, the effects of cryopreservation, concommitant induction, reagent glycosylation and the abrogation of IL-6 mediated suppression by a monoclonal antibody against IL-6.
This study shows that inclusion of IL-6 and an anti-IL-6 monoclonal antibody in human Cell culture. Suspension hepatoyctes from the vendor were spun at 100 x g for 10 minutes
and resuspended in plating media (William's E plus plating supplements: 5% fetal bovine serum, 100 nM dexamethasone, 100 U/mL penicillin and streptomycin, 4µg/mL insulin, 2mM
GlutaMAX™, 15mM HEPES, pH 7.4). Cryopreserved hepatocytes were thawed at 37ºC, spun at 100 x g in CHRM and resuspended in plating media. Viability and density were measured by trypan blue exclusion and 52,000 cells/well were plated onto 96-well collagen I coated plates.
Hepatocytes were allowed to attach for 4-6 hours, plating media was removed and replaced with maintenance media (DMEM plus maintenance supplements: 100 U/mL penicillin and streptomycin, 6.25 µg/mL insulin, 6.25 µg/mL transferrin, 6.25 ng/mL selenous acid, 1.25 mg/mL coli expressed IL-6 was used for all studies.
Analytical Conditions. The LC-MS/MS system was comprised of an Applied Biosystems 4000 Q-Trap equipped with an electrospray ionization source (Applied Biosystems, Foster City, CA)
coupled to an HPLC system consisting of two LC-20AD pumps with an in-line CBM-20A
controller and DGU-20A 5 solvent degasser (Shimadzu, Columbia, MD) and a LEAP CTC HTS PAL autosampler equipped with a dual-solvent self-washing system (CTC Analytics, Carrboro, NC). The injection volume was 20 µL for each analyte. LC separation was achieved using a Gemini C18 2.0 x 30 mm 5 µm column (Phenomenex, Torrance, CA). Gradient elution (flow rate = 500 µL/min) was carried out using a mobile phase system consisting of (A) 5 mM ammonium formate with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid with the following gradient 0-0.5 min, 5% (B); 0.5-1.75 min, 100% (B); 1.75-2 min, 5% (B). Source and gas parameters are as follows: Curtain gas: 10, collision gas: medium, ionspray voltage: 4500 V, temperature: 450°C.
Analysis of Acetaminophen Formation. Cells were washed with 100µL of KHB for 5 minutes. After removal, 100µL of KHB containing 100µM phenacetin was added to the cells and incubated on a rocking platform for 15 minutes in a 37°C incubator with 5% CO 2 . After the incubation period, 50µL was removed and added to 50µL acetonitrile containing 100nM tolbutamide (internal standard). Acetaminophen was measured by using multiple reaction monitoring with the following conditions: Q1: 151. 
Results
Effects of IL-6 Treatment on the Expression of Acute Phase Response Proteins. Primary hepatocytes from Donor Hu1153 were exposed to IL-6 for 72 hours. Over the concentration range 5 pg/mL-50 ng/mL IL-6, microscopic examination and an ATP assay showed that IL-6
was not toxic to hepatocytes from this donor (data not shown). IL-6 caused a marked increase in the acute phase proteins, C-reactive protein (CRP) and serum amyloid A (SAA) ( 
1 3 isoforms (Table 3) . CYP1A1 was the least sensitive to suppression by IL-6, with an EC 50 of 1,620 pg/mL while CYP3A4 was the most sensitive with an EC 50 of 3.2 pg/mL. While many P450 isoforms, such as CYP2B6, CYP2C8, CYP3A4, and CYP3A5, were down-regulated to below 5% of untreated cells, other isoforms such as CYP1A1, CYP1A2, CYP2C19, and CYP2D6 had a maximum suppression (E min ) of between 15-40% of untreated cells. The EC 50 for down-regulation of IL-6R mRNA was similar at 107 pg/mL (data not shown), showing that cells respond in a dynamic way to sustained stimulation by IL-6.
Donor Variability in the Effects of IL-6 on CYP1A2 and CYP3A4 Activity. To understand variability in the effect of IL-6 suppression on marker assays for two representative cytochrome P450 isoforms, three cryopreserved donors (Hu1001, Hu8064, and Hu4151) and two additional fresh donors (Hu1146 and Hu1150) were assessed. Donor characteristics can be found in the supplemental data (Supplemental Table 1 ). As shown in Table 4 and the supplemental data (Supplemental Figure 1 ), all donors had decreasing formation of both acetaminophen and 6β-hydroxytestosterone formation with increasing IL-6 concentrations. The EC 50 range for acetaminophen formation was 142-4070 pg/mL and 4.2-176 pg/mL for 6β-hydroxytestosterone formation. Maximal suppression for CYP1A2 activity ranged from 9.3-52.9% of untreated cells and for CYP3A4 activity the range was 10.7-41.7% of untreated cells.
The Effects of IL-6 on the Induction of CYP1A2 and CYP3A4. To examine IL-6-mediated suppression of CYP1A2 and CYP3A4 activity at different expression levels of cytochrome P450, hepatocytes from donor Hu4151 were treated for 72 h with IL-6 in the presence or absence of the CYP1A2 inducer omeprazole (50 µM) or CYP3A4 inducer rifampicin (10µM). Figure 3 shows that in the absence of IL-6, 8-and 4-fold induction occurred in omeprazole and rifampicintreated cells, respectively. IL-6 overcame the effects of both inducers, but only at concentrations greater than 500 pg/mL. The EC 50 of suppression of both CYP1A2 and CYP3A4 activity was shifted in the presence of inducer from 730 to 1120 pg/mL (1.5-fold) for CYP1A2 and from 82.8
to 1574 pg/mL (19-fold) for CYP3A4 (Table 4 ). The dynamic range of suppression by IL-6 was also affected in induced cells, with E min increasing almost 15-fold for CYP1A2 activity and 2-fold for CYP3A4 activity. IL-6-mediated suppression of the induced cytochrome P450 isoforms occurred at IL-6 concentrations that were well above those normally encountered in serum from patients with inflammatory disease (2.6-123 pg/mL, (Hidaka et al., 2001; Yilmaz et al., 2001; Arican et al., 2005; Ataseven et al., 2006; Wang et al., 2008) . Based on these in vitro data, suppression of cytochrome P450 activity by IL-6 does not override cytochrome P450 induction at physiological concentrations of IL-6.
The Effect of IL-6 Glycosylation Status on Cytochrome P450 Suppression. Because most commercial IL-6 is expressed in an E. coli system that lacks the capability to glycosylate proteins, IL-6 expressed in a human cell line, HEK293, was used to compare the extent of cytochrome P450 suppression between non-glycosylated and glycosylated versions of IL-6. IL-6 expressed in the HEK293 cell line had an observed molecular weight between 26-30 kDa and had variable glycosylation (manufacturer's data). Glycosylated and non-glycosylated IL-6 were examined using a kinetic exclusion assay (KinExA) to measure the dissociation constant (Kd) from the soluble IL-6 receptor. The measured Kd for the non glycosylated E. coli-expressed IL-6 was 5.1 nM (2.5-9.7 nM; 95% confidence interval) and was 3.2 nM (1.9-5.1 nM; 95% confidence interval) for HEK293 expressed IL-6. Figure 4 and Table 5 data from Donor Hu1190
show that the glycosylation state of IL-6 did not markedly change the EC 50 or E min data for suppression of CYP1A2 or CYP3A4 activity. Cytochrome P450 mRNA data for several cytochrome P450 isoforms gave similar results (Table 5) . Of these isoforms, no statistically significant change in EC 50 values was observed between glycosylated and non-glycosylated IL-6. There was also no statistically significant difference in the maximum extent of suppression
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De-suppression of Cytochrome P450 In Vitro: The Effect of an IL-6 Neutralizing Antibody on IL-6 Mediated Suppression of CYP1A2 and CYP3A4. To assess whether cytochrome P450 suppression by IL-6 can be blocked by a monoclonal antibody against non-glycosylated IL-6, 100 ng/mL of IL-6 neutralizing monoclonal antibody was added to hepatocytes in the presence of increasing concentrations of IL-6. To better understand the ability of this particular antibody to neutralize IL-6 activity and cause cytochrome P450 de-suppression, a dissociation constant was measured between non-glycosylated IL-6 and the monoclonal antibody. The Kd value was 1.7 nM, similar to the Kd value of IL-6 binding to IL-6R.
In two donors, the antibody blocked IL-6 suppression of CYP1A2 activity completely such that an EC 50 value could not be calculated for hepatocytes treated with both IL-6 and the anti-IL-6 antibody ( Figure 5 , Table 6 ). In donor Hu1242, CYP1A2 activity data in the absence of antibody was best fit to a bell-shaped dose response model with CYP1A2 activity initially increasing between 10 and 1000 pg/mL IL-6 and then decreasing to an E min of 20%. In the presence of antibody, this effect was right-shifted with an increase in CYP1A2 activity of 171%
of untreated cells at 1000 pg/mL and a subsequent decrease to 128% at 10 ng/mL.
Treatment with the IL-6 antibody did not completely abolish CYP3A4 suppression by IL-6, but did shift the EC 50 curve 19-fold from 92.5 to 1738 pg/mL in Donor Hu1242 and 13-fold from 63.6 to 849 pg/mL in Donor Hu8110 ( Figure 5 , Table 6 ). The maximum level of suppression was not markedly altered by the IL-6 antibody at the highest IL-6 concentrations. pathway with involvement of NF-κB subunits p50 and p65 (Zhang et al., 1996; Jensen and Whitehead, 1998) , and there is also a complex synergistic interaction between STAT3 and C/EBP that activates transcription of C-reactive protein. Therefore, the ability of IL-6 to cause a dose dependent increase in both C-reactive protein and serum amyloid A in our study is indicative of an acute phase response and is consistent with previous reports indicating that our human hepatocyte culture conditions were suitable for studying IL-6 signaling.
Under the standardized conditions established to monitor the effects of IL-6 on hepatocytes, dexamethasone was not added to the culture medium, as it complicates the hepatocyte model.
Dexamethasone acts as a potent anti-inflammatory agent by controlling levels of leukotrienes and prostaglandins and enhancing cytochrome P450 levels (Pascussi et al., 2000a; Pascussi et al., 2000b; Brunton, 2011) . It also up-regulates the levels of IL-6 receptor on certain cell types (Snyers et al., 1990; Hoffmann et al., 1994) and enhances the effects of cytokines (Steel and Whitehead, 1994; Thorn and Whitehead, 2002) . In a pilot experiment, the addition of 100 nM dexamethasone increased IL-6R mRNA by 3.5-fold and CYP3A4 mRNA by 5-fold (Supplemental Figure 2) . These increases are within the natural variation seen in donor populations. In this study, the absence of dexamethasone in the cell culture medium did not substantially alter basal cell stress levels. This was shown by similar ATP and GSH production
at IL-6 concentrations up to 500 ng/mL. The mRNA levels of ER stress markers, CHOP and BIP, were slightly higher in IL-6 naïve, dexamethasone-treated cells (Supplemental Figure 2) .
Effects of IL-6 on Cytochromes P450. This study expands upon previous studies exploring IL-6 regulation of cytochrome P450 enzymes in human hepatocyte culture (Yang et al.; Aitken and Morgan, 2007; Lee et al., 2009 ). In part because of regulatory interest, dissecting out the components of the APR is of industrial interest, since companies working on an anti-cytokine drug want to know whether their cytokine alone elicits this effect on cytochrome P450s. Thus our approach to reconstituting the APR in this model is cytokine-centric and differs from more complicated disease-specific/multi-cytokine (i.e. LPS) approaches.
We focused on several key aspects that have not been previously reported: A) the use of physiologically relevant IL-6 concentrations; B) biochemical characterization of commercial protein reagents and; C) the ability of an anti-IL-6 monoclonal antibody to block the effects of IL-6 on cytochrome P450s. Our data were comparable to previously published results in that cytochrome P450s were generally down-regulated by treatment with IL-6, although direct comparison among studies are problematic due to different commercial sources of cytokines and cytokine concentrations.
CYP3A4 was chosen as a marker for four reasons: 1) It is the enzyme responsible for metabolizing the majority of marketed drugs, 2) mRNA data indicated it was the most sensitive isoform to IL-6 challenge; 3) it is the responsible enzyme in the 1. 
1 8 fresh hepatocytes were not significantly different, suggesting they are both appropriate for investigating cytochrome P450 regulation by IL-6.
To address the role of basal expression of CYP3A4 in IL-6 mediated CYP3A4 expression,
we examined suppression of CYP3A4 activity by IL-6 in hepatocytes induced by rifampicin. The EC 50 for suppression of CYP3A4 activity by IL-6 was shifted by rifampicin from 82.8 to 1574
pg/mL (19 fold, Table 4 ). Based on normal ranges for IL-6 concentrations in serum, suppression of cytochrome P450 activity by IL-6 only overrode cytochrome P450 induction at supraphysiological concentrations of IL-6.
Treatment of human hepatocytes with IL-6 generally caused pan-suppression of mRNA for all cytochrome P450 isoforms with EC 50 and E min values varying amongst cytochrome P450
isoforms and for the same isoform between donors. IL-6 itself was not measured in the media and this precludes adjustment for possible substrate depletion. However, the EC 50 data did define differences in responsiveness of individual cytochrome P450s at identical IL-6 concentrations and enabled rank ordering of cytochrome P450 sensitivity to IL-6. PXR/CAR regulated isoforms CYP3A4 and CYP2B6 were the most sensitive to down-regulation by IL-6, whereas AhR-regulated isoforms CYP1A1 and CYP1A2 were the least sensitive. Given the EC 50 values of suppression for the individual cytochrome P450 isoforms and the physiological serum concentrations of IL-6, we speculate that CYP1A2 levels will not be altered significantly by anti-cytokine treatments for inflammatory disease.
Because IL-6 is differentially glycosylated in vivo, we investigated the effect of IL-6 glycosylation on cytochrome P450 suppression in human hepatocytes. 
1 9 glycosylated forms were within 2-fold of one another. These data indicate that once bound both the glycosylated and non-glycosylated forms of IL-6 dissociate from the IL-6 receptor with equal
potency.
An anti-IL-6 antibody was able to block IL-6 suppression of CYP1A2 activity in two donors such that an EC 50 value could not be calculated. At supratherapeutic concentrations (500-10,000 pg/mL), IL-6 anomalously increased CYP1A2 activity relative to initial conditions. The mechanism behind this observation is currently not understood. Treatment with the anti-IL-6
antibody did not completely abolish CYP3A4 suppression by IL-6, but did shift the EC 50 curve 19-fold and 13-fold in two different donors, respectively. The dissociation constant for the antibody used in this study was 1.7 nM, which is similar to the measured Kd values between IL-6 and its receptor (3.2-5.1 nM). However, the Kd value for the IL-6/IL-6R/gp130 complex, the active complex for IL-6 signaling, has been measured at 50 pM (Hibi et al., 1990 ). This could explain why CYP3A4 suppression was only partially blocked by the antibody used in this study 
2 0 not affect CYP3A4 suppression by IL-6 or IL-1, suggesting that co-culture may not be necessary for investigating cytochrome P450 suppression by IL-1 or IL-6 alone.
We demonstrated that IL-6 down-regulates its own receptor in human hepatoycte culture suggesting a potential adaptive response mechanism. Cultured hepatocytes are viable for a relatively short time period and therefore may not be the best model for discerning adaptive responses to cytokine stimulation. Advanced tissue engineering technologies such as threedimensional liver culture or the HepatoPac™ platform might better define the adaptive response of hepatocytes to IL-6 and other cytokines.
This study shows that inclusion of IL-6 and an anti-IL-6 monoclonal antibody in human hepatocyte primary culture allows for quantitative measurement of cytochrome P450 suppression and de-suppression. However, the experiments also illustrate that these data cannot fully address the complicated biology of the acute phase response and/or chronic inflammation in human liver. Factors that complicate the predictive value of the experiments are the biology of the individual cytokine, relevant hepatic concentrations of the cytokine, the binding affinities of relevant monoclonal antibodies, the absence of other interacting cytokines and cell types in primary hepatocyte culture and the nuances of patient and disease-specific aspects of inflammatory disease.
We conclude that experimentation with a single cytokine in human hepatocyte primary culture will be useful for hypothesis generation. However, the complicated biology of inflammatory disease treatment precludes quantitative in vitro to in vivo prediction of the clinical effects of anti-cytokine treatment on the pharmacokinetics of small molecule concomitant medications. 
